Fungal Drug Discovery for Chronic Disease: History, New Discoveries and New Approaches

被引:21
作者
Prescott, Thomas A. K. [1 ]
Hill, Rowena [2 ]
Mas-Claret, Eduard [1 ]
Gaya, Ester [1 ]
Burns, Edie [1 ]
机构
[1] Royal Bot Gardens, Richmond TW9 3AB, Surrey, England
[2] Earlham Inst, Norwich NR4 7UZ, Norfolk, England
关键词
fungi; drugs; self-resistance; ecological function; drug distribution; mechanism of action; PENICILLIUM-CHRYSOGENUM; METABOLIC PRODUCT; GANODERMA; MECHANISM; BIOSYNTHESIS; MUSHROOM; AGENT; ANTROQUINONOL; RESISTANCE; INHIBITOR;
D O I
10.3390/biom13060986
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Fungal-derived drugs include some of the most important medicines ever discovered, and have proved pivotal in treating chronic diseases. Not only have they saved millions of lives, but they have in some cases changed perceptions of what is medically possible. However, now the low-hanging fruit have been discovered it has become much harder to make the kind of discoveries that have characterised past eras of fungal drug discovery. This may be about to change with new commercial players entering the market aiming to apply novel genomic tools to streamline the discovery process. This review examines the discovery history of approved fungal-derived drugs, and those currently in clinical trials for chronic diseases. For key molecules, we discuss their possible ecological functions in nature and how this relates to their use in human medicine. We show how the conservation of drug receptors between fungi and humans means that metabolites intended to inhibit competitor fungi often interact with human drug receptors, sometimes with unintended benefits. We also plot the distribution of drugs, antimicrobial compounds and psychoactive mushrooms onto a fungal tree and compare their distribution to those of all fungal metabolites. Finally, we examine the phenomenon of self-resistance and how this can be used to help predict metabolite mechanism of action and aid the drug discovery process.
引用
收藏
页数:25
相关论文
共 50 条
  • [31] Epigenetic polypharmacology: A new frontier for epi-drug discovery
    Tomaselli, Daniela
    Lucidi, Alessia
    Rotili, Dante
    Mai, Antonello
    MEDICINAL RESEARCH REVIEWS, 2020, 40 (01) : 190 - 244
  • [32] New plant disease records in New Zealand: Miscellaneous fungal pathogens .3.
    McKenzie, EHC
    Dingley, JM
    NEW ZEALAND JOURNAL OF BOTANY, 1996, 34 (02) : 263 - 272
  • [33] Drugs Polypharmacology by In Silico Methods: New Opportunities in Drug Discovery
    Lauria, Antonino
    Bonsignore, Riccardo
    Bartolotta, Roberta
    Perricone, Ugo
    Martorana, Annamaria
    Gentile, Carla
    CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (21) : 3073 - 3081
  • [34] New approaches to secondary metabolite discovery from anaerobic gut microbes
    Butkovich, Lazarina V.
    Vining, Oliver B.
    O'Malley, Michelle A.
    APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2025, 109 (01)
  • [35] Revisiting Old Questions and New Approaches to Investigate the Fungal Cell Wall Construction
    Blatzer, Michael
    Beauvais, Anne
    Henrissat, Bernard
    Latge, Jean-Paul
    FUNGAL CELL WALL: AN ARMOUR AND A WEAPON FOR HUMAN FUNGAL PATHOGENS, 2020, 425 : 331 - 369
  • [36] Drug Discovery to Halt the Progression of Acute Kidney Injury to Chronic Kidney Disease: A Case for Phenotypic Drug Discovery in Acute Kidney Injury
    Hukriede, Neil
    Vogt, Andreas
    de Caestecker, Mark
    NEPHRON, 2017, 137 (04) : 268 - 272
  • [37] New Perspectives in the Diagnosis and Management of Allergic Fungal Airway Disease
    Wardlaw, Andrew J.
    Rick, Eva-Maria
    Ozyigit, Leyla Pur
    Scadding, Alys
    Gaillard, Erol A.
    Pashley, Catherine H.
    JOURNAL OF ASTHMA AND ALLERGY, 2021, 14 : 557 - 573
  • [38] Supporting supervised learning in fungal Biosynthetic Gene Cluster discovery: new benchmark datasets
    Almeida, Hayda
    Tsang, Adrian
    Diallo, Abdoulaye Banire
    2019 IEEE INTERNATIONAL CONFERENCE ON BIOINFORMATICS AND BIOMEDICINE (BIBM), 2019, : 1280 - 1287
  • [39] New drug discovery strategies for the treatment of benznidazole-resistance in Trypanosoma cruzi, the causative agent of Chagas disease
    Fonseca Murta, Silvane Maria
    Lemos Santana, Pedro Augusto
    Jacques Dit Lapierre, Thibault Joseph William
    Penteado, Andre Berndt
    El Hajje, Marissa
    Navarro Vinha, Thabata Corazza
    Liarte, Daniel Barbosa
    de Souza, Mariana Laureano
    Goulart Trossini, Gustavo Henrique
    de Oliveira Rezende Junior, Celso
    de Oliveira, Renata Barbosa
    Ferreira, Rafaela Salgado
    EXPERT OPINION ON DRUG DISCOVERY, 2024, 19 (06) : 741 - 753
  • [40] Methotrexate: an old new drug in autoimmune disease
    Cipriani, Paola
    Ruscitti, Piero
    Carubbi, Francesco
    Liakouli, Vasiliki
    Giacomelli, Roberto
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2014, 10 (11) : 1519 - 1530